Department of General Pediatrics and Pediatric Infectious Diseases, Reference Center for Sickle Cell Disease, Necker Hospital for Sick Children, Assistance Publique - Hôpitaux de Paris (AP-HP), Université de Paris, Paris; Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutical Implications, Université de Paris, Imagine Institute, Inserm U1163, Paris; Laboratory of Excellence GR-Ex.
Department of General Pediatrics and Pediatric Infectious Diseases, Reference Center for Sickle Cell Disease, Necker Hospital for Sick Children, Assistance Publique - Hôpitaux de Paris (AP-HP), Université de Paris, Paris; Laboratory of Excellence GR-Ex, Paris; Paris-Cardiovascular Research Centre (PARCC), Université de Paris, Inserm U970.
Haematologica. 2021 Jun 1;106(6):1535-1544. doi: 10.3324/haematol.2020.271353.
Median life expectancy of patients with sickle cell disease has increased to up to 55 years but there are still frequent cases of premature death, mostly in patients with pre-existing organ failure such as pulmonary hypertension, kidney injury, and cerebral vasculopathy. Most organ injuries remain asymptomatic for a long time and can only be detected through early systematic screening. Protocols combining assessment of velocities on transcranial Doppler and regular transfusions in patients with abnormal velocities have been demonstrated to dramatically reduce the risk of stroke. In contrast, no consensus has been reached on systematic screening or therapy for silent cerebral infarcts. The prognostic significance of increased tricuspid regurgitant jet velocity on echocardiography has not yet been identified in children, whereas increased albuminuria is a good predictor of kidney injury. Finally, screening for hip and eye disorder is recommended; however, different countries adopt different screening strategies. Hydroxyurea is probably of potential benefit in preventing chronic organ damage but this requires further study in order to be fully demonstrated. Efficacy and safety of the other new drugs available are also under investigation.
镰状细胞病患者的中位预期寿命已延长至 55 岁,但仍有频繁的过早死亡病例,主要发生在已有肺高压、肾损伤和脑血管病等器官衰竭的患者中。大多数器官损伤在很长一段时间内都没有症状,只能通过早期系统筛查发现。已经证明,结合经颅多普勒流速评估和异常流速患者定期输血的方案可以显著降低中风风险。相比之下,对于无症状性脑梗死的系统筛查或治疗尚未达成共识。在儿童中,超声心动图上三尖瓣反流射流速度增加的预后意义尚未确定,而白蛋白尿增加是肾损伤的良好预测指标。最后,建议筛查髋关节和眼部疾病;然而,不同国家采用不同的筛查策略。羟基脲可能对预防慢性器官损伤有潜在益处,但需要进一步研究才能充分证明。其他现有新药的疗效和安全性也在研究中。